Summary & Overview
HCPCS G2079: Take-Home Oral Buprenorphine, Up to 7-Day Supply
HCPCS Level II code G2079 designates the take-home dispensing of oral buprenorphine—up to a 7-day additional supply—when provided by a Medicare-enrolled opioid treatment program. This code enables separate reporting for take-home medication supplies in addition to primary treatment procedure codes, reflecting evolving care models that expand access to medication for opioid use disorder (MOUD). Nationally, the code matters because it supports documentation and reimbursement pathways that influence patient access to short take-home supplies and the operational workflows of opioid treatment programs.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical and administrative purpose, payer coverage context, and what to expect in documentation and billing practice. The publication summarizes benchmarks and policy-relevant points affecting use of G2079, including billing scope and common clinical settings where the service is rendered. It also identifies areas where input data was not provided, such as associated taxonomies, ICD-10 pairings, and related codes, so readers understand the limits of the current overview.
The report is intended for billing professionals, compliance officers, and clinical administrators seeking a national-level briefing on the code’s role in MOUD delivery and claims reporting.
Billing Code Overview
HCPCS Level II code G2079 describes the take-home supply of buprenorphine (oral) provided by a Medicare-enrolled opioid treatment program. The code covers up to an additional 7-day supply of buprenorphine furnished to a patient and is reported separately in addition to the code for the primary procedure.
Service Type: Medication dispensing for opioid use disorder treatment (take-home buprenorphine supply)
Typical Site of Service: Opioid treatment program or other outpatient substance use treatment setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient with opioid use disorder (OUD) attends a Medicare-enrolled opioid treatment program (OTP) for ongoing medication-assisted treatment. The patient is clinically stabilized on sublingual buprenorphine and qualifies for take-home medication privileges for up to an additional seven days based on program policies, documented adherence, and toxicology results. The OTP clinician documents the take-home dispensing event in the medical record, records the amount and days’ supply provided, and bills the service using G2079 in addition to the primary OTP visit/procedure code. Typical workflow: intake assessment and treatment planning by an OTP provider (physician, nurse practitioner, or physician assistant), urine drug testing and counseling visit as required, determination of take-home eligibility, pharmacist or designated staff prepares and dispenses the up-to-7-day buprenorphine supply, and the program records counseling or monitoring notes and dispensation details for billing and quality tracking. Typical site of service: Medicare-enrolled opioid treatment program (OTP) outpatient clinic or OTP-licensed dispensing pharmacy integrated with the program.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure has no modifier | Default primary reporting when no modifier applies |